Matthias Von Herrath

Company: Novo Nordisk
Job title: Vice President & Senior Medical Officer, Global Chief Medical Office
Seminars:
Can Antigen Specific Immune Therapy Control Tissue Resident Effector T cells in Human Type 1 Diabetes? 11:30 am
day: Day Two